Search results for "radium 223"

showing 2 items of 2 documents

Can radium 223 be a conservative non-surgical management of medication-related osteonecrosis of the jaw?

2019

AbstractOsteonecrosis of the jaw (ONJ) is a rare and severe necrotic bone disease reflecting a compromise in the body's osseous healing mechanisms and unique to the craniofacial region. Radium 223 dichloride (Ra223) is the only targeted alpha therapy able to extend survival in patients with bone metastases from prostate cancer. Mechanism of action and data currently available focused mainly on osteoblastic metastases from prostate cancer. In 2018, a Caucasian 54-year-old woman presented to our institution for a breast cancer with bone metastases. Since the patient refused any treatment and taking into account the bone disease, our multidisciplinary team evaluated a supplementary strategy wi…

lcsh:Medical physics. Medical radiology. Nuclear medicineRadium-223medicine.medical_specialtyBone diseaselcsh:R895-920Case Report030218 nuclear medicine & medical imagingradium 22303 medical and health sciencesProstate cancerbreast cancer0302 clinical medicineBreast cancermedicineCraniofacialProspective cohort studybusiness.industryBone metastasesCancermedicine.diseaseSurgeryBone metastaseosteonecrosis of the jaw030220 oncology & carcinogenesisbusinessOsteonecrosis of the jawmedicine.drugWorld Journal of Nuclear Medicine
researchProduct

Ra223 in bone metastases with osteolytic activity

2018

Radium 223 dichloride (Ra223) is the only targeted alpha therapy able to extend survival in patients with bone metastases from prostate cancer. Mechanism of action and data currently available focused mainly on osteoblastic metastases from prostate cancer. In our institution, a patient with breast cancer affected by osteolytic metastases was treated with off-label use of Ra223. The evaluation of the deposit areas of Ra223 showed a perfect overlap with the regions of osteolysis previously detected by scintigraphy, indicating a possible therapeutic effect. This case report is the first document attesting Ra223 deposit in osteolytic metastases opening new opportunity of therapeutic development…

Radium-223lcsh:Medical physics. Medical radiology. Nuclear medicinemedicine.medical_specialtyOsteolysislcsh:R895-920Case ReportScintigraphy030218 nuclear medicine & medical imagingradium 22303 medical and health sciencesProstate cancer0302 clinical medicineBreast cancerbreast cancerosteoblastic bone metastasesmedicineIn patientRadium-223 Dichlorideosteolytic bone metastasesmedicine.diagnostic_testbusiness.industryBone metastasesTherapeutic effectmedicine.disease030220 oncology & carcinogenesisRadiologybusinessmedicine.drugWorld Journal of Nuclear Medicine
researchProduct